Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MERU maintenance study of rovalpituzumab tesirine in extensive-stage small cell lung cancer
2016-003503-64Phase 3Terminated
- Sponsor
- AbbVie Inc.
- Start
- Mar 2017
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 3 trial of rovalpituzumab tesirine in small cell lung cancer (SCLC), sponsored by AbbVie Inc.. Started Mar 2017; status: terminated.
02
Drugs
rovalpituzumab tesirine
03
Conditions
small cell lung cancer (SCLC)
Beyond the preview
Go deeper on 2016-003503-64.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2016-003503-64.